Merck helps bankroll new partner Themis' game plan to finish the chikungunya race and begin oncolytic virus quest
As Themis gears up for a Phase III trial of its chikungunya vaccine, the Vienna-based biotech has closed out €40 million ($44 million) to foot …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
